Literature DB >> 18752570

Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2.

P C J Armstrong1, N J Truss, F Y Ali, A A Dhanji, I Vojnovic, Z N M Zain, D Bishop-Bailey, M J Paul-Clark, A T Tucker, J A Mitchell, T D Warner.   

Abstract

BACKGROUND: Currently, 'aspirin resistance', the anti-platelet effects of non-steroid anti-inflammatory drugs (NSAIDs) and NSAID-aspirin interactions are hot topics of debate. It is often held in this debate that the relationship between platelet activation and thromboxane (TX) A(2) formation is non-linear and TXA(2) generation must be inhibited by at least 95% to inhibit TXA(2)-dependent aggregation. This relationship, however, has never been rigorously tested.
OBJECTIVES: To characterize, in vitro and ex vivo, the concentration-dependent relationships between TXA(2) generation and platelet activity.
METHOD: Platelet aggregation, thrombi adhesion and TXA(2) production in response to arachidonic acid (0.03-1 mmol L(-1)), collagen (0.1-30 microg mL(-1)), epinephrine (0.001-100 micromol L(-1)), ADP, TRAP-6 amide and U46619 (all 0.1-30 micromol L(-1)), in the presence of aspirin or vehicle, were determined in 96-well plates using blood taken from naïve individuals or those that had taken aspirin (75 mg, o.d.) for 7 days.
RESULTS: Platelet aggregation, adhesion and TXA(2) production induced by either arachidonic acid or collagen were inhibited in concentration-dependent manners by aspirin, with logIC(50) values that did not differ. A linear relationship existed between aggregation and TXA(2) production for all combinations of arachidonic acid or collagen and aspirin (P < 0.01; R(2) 0.92; n = 224). The same relationships were seen in combinations of aspirin-treated and naïve platelets, and in blood from individuals taking an anti-thrombotic dose of aspirin.
CONCLUSIONS: These studies demonstrate a linear relationship between inhibition of platelet TXA(2) generation and TXA(2)-mediated aggregation. This finding is important for our understanding of the anti-platelet effects of aspirin and NSAIDs, NSAID-aspirin interactions and 'aspirin resistance'.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752570     DOI: 10.1111/j.1538-7836.2008.03133.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  19 in total

1.  Recurrent myocardial infarction associated with gefitinib therapy.

Authors:  Donald R Lynch; Thomas S Kickler; Jeffrey J Rade
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

Review 2.  Refinement, reduction and replacement approaches to in vivo cardiovascular research.

Authors:  Michael Emerson
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC.

Authors:  Annachiara Mitrugno; Joanna L Sylman; Anh T P Ngo; Jiaqing Pang; Rosalie C Sears; Craig D Williams; Owen J T McCarty
Journal:  Am J Physiol Cell Physiol       Date:  2016-11-30       Impact factor: 4.249

4.  Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device.

Authors:  Jawaad Sheriff; Gaurav Girdhar; Wei-Che Chiu; Jolyon Jesty; Marvin J Slepian; Danny Bluestein
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

5.  Characterization of platelet dysfunction after trauma.

Authors:  Matthew E Kutcher; Brittney J Redick; Ryan C McCreery; Ian M Crane; Molly D Greenberg; Leslie M Cachola; Mary F Nelson; Mitchell Jay Cohen
Journal:  J Trauma Acute Care Surg       Date:  2012-07       Impact factor: 3.313

6.  Celecoxib interferes to a limited extent with aspirin-mediated inhibition of platelets aggregation.

Authors:  Mark Ruzov; Gilad Rimon; Oleg Pikovsky; David Stepensky
Journal:  Br J Clin Pharmacol       Date:  2015-12-15       Impact factor: 4.335

7.  Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity.

Authors:  A P DeFilippis; S N Rai; A Cambon; R J Miles; A S Jaffe; A B Moser; R O Jones; R Bolli; S P Schulman
Journal:  Nutr Metab Cardiovasc Dis       Date:  2013-10-23       Impact factor: 4.222

8.  In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.

Authors:  P C J Armstrong; P D Leadbeater; M V Chan; N S Kirkby; J A Jakubowski; J A Mitchell; T D Warner
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

9.  Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction.

Authors:  Paul C J Armstrong; Nicholas S Kirkby; Melissa V Chan; Michaela Finsterbusch; Nancy Hogg; Sussan Nourshargh; Timothy D Warner
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

Review 10.  Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.

Authors:  Mark R Thomas; Robert F Storey
Journal:  J Cardiovasc Transl Res       Date:  2013-12-06       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.